Ultragenyx Stock Performance
| RARE Stock | USD 39.68 0.82 2.11% |
The entity has a beta of 0.94, which indicates possible diversification benefits within a given portfolio. Ultragenyx returns are very sensitive to returns on the market. As the market goes up or down, Ultragenyx is expected to follow. At this point, Ultragenyx has a negative expected return of -0.12%. Please make sure to validate Ultragenyx's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Ultragenyx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.11 | Five Day Return 0.92 | Year To Date Return (3.57) | Ten Year Return (36.91) | All Time Return (6.08) |
Last Split Factor 1:3 | Last Split Date 2014-01-17 |
1 | Disposition of 11727 shares by Kakkis Emil D of Ultragenyx at 42.23 subject to Rule 16b-3 | 12/30/2024 |
2 | Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/06/2025 |
3 | Disposition of 9806 shares by Parschauer Karah Herdman of Ultragenyx at 45.0 subject to Rule 16b-3 | 01/21/2025 |
4 | Ultragenyxs SWOT analysis rare disease stock poised for growth | 01/22/2025 |
5 | Ultragenyx Q4 Earnings Taking a Look at Key Metrics Versus Estimates | 02/13/2025 |
6 | Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application ... | 02/18/2025 |
7 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 02/19/2025 |
8 | Ultragenyx to Participate at Investor Conferences in March - GlobeNewswire | 02/24/2025 |
9 | Disposition of 760 shares by Parschauer Karah Herdman of Ultragenyx at 42.75 subject to Rule 16b-3 | 02/27/2025 |
10 | Disposition of 25000 shares by Kakkis Emil D of Ultragenyx at 42.48 subject to Rule 16b-3 | 02/28/2025 |
11 | Disposition of 141 shares by Theodore Huizenga of Ultragenyx at 42.92 subject to Rule 16b-3 | 03/03/2025 |
12 | Acquisition by Howard Horn of 15653 shares of Ultragenyx subject to Rule 16b-3 | 03/04/2025 |
13 | Ultragenyx Pharmaceutical Inc. EVP Sells 128,211.20 in Stock | 03/06/2025 |
14 | Gene Therapy Market Global Forecast to 2032 Biopharma Giants Lead Gene Therapy Market Expansion Latest Developments Projections | 03/07/2025 |
15 | Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Frag... | 03/11/2025 |
16 | Disposition of 7500 shares by Fust Matthew K of Ultragenyx at 50.88 subject to Rule 16b-3 | 03/13/2025 |
17 | Acquisition by Crombez Eric of 14971 shares of Ultragenyx subject to Rule 16b-3 | 03/14/2025 |
18 | Alkaptonuria Therapeutics Market to Reach US 31.6 Million by 2035 with Rising Demand for Orphan Drugs Exclusive Report by Transparency Market Research, Inc. | 03/18/2025 |
| Begin Period Cash Flow | 219.4 M |
Ultragenyx |
Ultragenyx Relative Risk vs. Return Landscape
If you would invest 4,347 in Ultragenyx on December 19, 2024 and sell it today you would lose (379.00) from holding Ultragenyx or give up 8.72% of portfolio value over 90 days. Ultragenyx is currently does not generate positive expected returns and assumes 2.4364% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Ultragenyx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ultragenyx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ultragenyx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ultragenyx, and traders can use it to determine the average amount a Ultragenyx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0503
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RARE |
Estimated Market Risk
| 2.44 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ultragenyx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ultragenyx by adding Ultragenyx to a well-diversified portfolio.
Ultragenyx Fundamentals Growth
Ultragenyx Stock prices reflect investors' perceptions of the future prospects and financial health of Ultragenyx, and Ultragenyx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ultragenyx Stock performance.
| Return On Equity | -2.12 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.02) % | ||||
| Operating Margin | (0.74) % | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 92.5 M | ||||
| Price To Earning | (6.90) X | ||||
| Price To Book | 14.36 X | ||||
| Price To Sales | 6.42 X | ||||
| Revenue | 560.23 M | ||||
| Gross Profit | (214.36 M) | ||||
| EBITDA | (469 M) | ||||
| Net Income | (569.18 M) | ||||
| Cash And Equivalents | 542.8 M | ||||
| Cash Per Share | 7.75 X | ||||
| Total Debt | 10.3 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 2.76 X | ||||
| Cash Flow From Operations | (414.19 M) | ||||
| Earnings Per Share | (6.29) X | ||||
| Market Capitalization | 3.59 B | ||||
| Total Asset | 1.5 B | ||||
| Retained Earnings | (3.96 B) | ||||
| Working Capital | 472.97 M | ||||
| Current Asset | 416.79 M | ||||
| Current Liabilities | 50.43 M | ||||
About Ultragenyx Performance
By analyzing Ultragenyx's fundamental ratios, stakeholders can gain valuable insights into Ultragenyx's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ultragenyx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ultragenyx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 214.10 | 203.40 | |
| Return On Tangible Assets | (0.44) | (0.47) | |
| Return On Capital Employed | (0.46) | (0.49) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (2.23) | (2.12) |
Things to note about Ultragenyx performance evaluation
Checking the ongoing alerts about Ultragenyx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ultragenyx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ultragenyx generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 560.23 M. Net Loss for the year was (569.18 M) with loss before overhead, payroll, taxes, and interest of (214.36 M). | |
| Ultragenyx currently holds about 542.8 M in cash with (414.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.75. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Alkaptonuria Therapeutics Market to Reach US 31.6 Million by 2035 with Rising Demand for Orphan Drugs Exclusive Report by Transparency Market Research, Inc. |
- Analyzing Ultragenyx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ultragenyx's stock is overvalued or undervalued compared to its peers.
- Examining Ultragenyx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ultragenyx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ultragenyx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ultragenyx's stock. These opinions can provide insight into Ultragenyx's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ultragenyx Stock analysis
When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |